Topotecan, a new topoisomerase I-inhibitor with potential radiosensitizing effect;Topoisomerase-I-Inhibitor mit potentiell strahlen-sensibilisierender Wirkung

Strahlentherapie und Onkologie

Volumn 173, Issue 3, 1997, Pages 125-130

  Sauer, R ^a   Heuser, A ^b  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b SmithKline Beecham   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE INHIBITOR; TOPOTECAN;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; HUMAN; NONHUMAN; RADIOSENSITIZATION; REVIEW;

EID: 0030888314     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03039268     Document Type: Review

References (39)

1. Anzai, H., P. Frost, J. L. Abbruzzese: Synergistic cytotoxicity with combined inhibition of Topoisomerase (Topo I) and II. Proc. Ann. Meet. Amer. Ass. Cancer. Res. 33 (1992), abstract 2573.
2. Armstrong, E., R. Rowinsky, R. Donehower, N. Rosenshein, J, Walezak, W. McGuire: A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer. Proc. ASCO 14 (1995), abstract 769.
3. Baker S. D., R. L. Heideman, W. R. Crom, J. F. Kuttesch, A. Gajjar, C. F. Stewart: Cerebrospinal fluid pharmacokinetics and penetration of continuous topotecan in children with central nervous system tumors. Cancer Chemother. Pharmacol. 37 (1996), 195-202.
4. Beijnen, J. H.: Clinical pharmacokinetics and pharmaco-dynamics of topotecan (abstract). Proc. 6th Conf. on DNA topoisomerases in therapy, Amsterdam 1996.
5. Berlin, J., J. H. Schiller, P. R. Hudson, C. Feierabend, K. Simon, D. Alberti, R. Arzoomanian, D. Boothman, S. Planchon, S. Wuerzberger, V. Glen, M. Mehta, G. Wilding: Phase 1 clinical and pharmacokinetic study of daily topotecan with thoracic irradiation. Proc. Amer. Ass. Cancer Res. 37 (1996), abstract 1131.
6. Blaney. S, F. Balis, D. Cole, C. Graig, J. Reid, M. Ames: Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res. 43 (1993), 1032-1036.
7. Bokkel Huinink, W. ten, M. Gore, G. Bolis, J. Verweij, JF. Lacave, G. Scarfone, J. Guastalla, S. Van Belle, R. Despax, G. Favalli, L Hudson, R. Kreienberg: A phase II trial of topotecan for the treatment of advanced ovarian carcinoma. Proc. ASCO 1 (1996), abstract 768.
8. Boothman, D. A., D. K. Trask, A. B. Pardee: Inhibition of potential lethal damage repair in human Tumor cells by β-lapachone, an activator of topoisomerase I. Cancer Res. 49 (1987), 605-612.
9. Boscia, R. E., T. Korbut, S. A. Holden, B. A. Teicher: Interaction of topoisomerase I inhibitors with radiation in cis-diamminedichloroplatinum(II)-sensitive and -resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo. Int. J. Cancer 53 (1993), 118-123.
10. Burch, P. A., P.J. Novotony, A. M. Bernath, T. L. Cascino, F. K. Addo, M. D. Keppen, J. W. Kugler, J. C. Buckner: A North Cancer Treatment Group phase II trial of topotecan in relapsed gliomas. Proc. Amer. Ass. Cancer Res. 37 (1996), abstract 1164.
11. Burns, H. A., A. R. Hanauske, R. K. Johnson, M. H. Marshall, J. G. Kuhn, S. G. Hilsenbeck, D. O. von Hoff: Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J. nat. Cancer Inst. 84 (1992), 1816-1820.
12. Carmichael, J., A. Gordon, J. Malfetano, M. Gore, M. Spaczynski, N. Davidson, J. Savage, D. Clark-Pearson, I. Hudson, C. Broom, W. ten Bokkel Huinink. Topotecan, a new active drug, vs. paclitaxel in advanced epithelial ovarian carcinoma. Proc. ASCO 15 (1996), abstract 765.
13. Chang, A. Y., C. Z. Gu, P. Keng, S. Sobel: Topotecan and etoposide inhibit radiation repair differently than potential lethal damage. Proc. Amer. Ass. Cancer Res. 33 (1992), abstract 2609.
14. Chen, A. Y., L. F. Liu: DNA topoisomerases: essential enzymes and lethal targets. Ann. Rev. Pharmacol. Toxicol. 34 (1994), 191-218.
15. Cheng, M. F., S. Chatterjee, N. A. Berger: Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol. Res. 6 (1994), 269-279.
16. Creemers, G. J., C. J. H. Gerrits, J. H. M. Schellens, A. S. T. Planting, M. E. L. v. d. Burg, V. M. van Beurden, M. de Boer-Dennert, M. Harteveld, W. Loos, I. Hudson, G. Stoter, J. Verweij: Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer. J. clin. Oncol. (1996), 2540-2545.
17. Danks, M. K., R. C. Marion: Comparison of intermittent and continuous exposure to topotecan in medulloblastoma cells. Proc. Amer. Ass. Cancer Res. 37 (1996), absract 2977.
18. Gordon, A., M. Bookman, H. Maunström, G. Bolis, C. Mangioni, J. Hall, J. Carter, I. Hudson, C. Broom: Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel. Proc. ASCO 15 (1996), abstract 763.
19. Graham, M. V., M. Jahanzeb, C. Dresler, J. Cooper, B. Emami, J. Mortimer: Preliminary results of a phase I study of topotecan plus thoracic radiotherapy for locally advanced non-small cell lung cancer (NSCLCA). Proc. ASCO 13 (1994), abstract 1132.
20. Hochster, H., L. Liebes, J. Speyer, J. Sorich, B. Taubes, R. Oratz, J. Wernz, A. Chachoua B. Raphael, R. Z. Vinci, R. H. Blum: Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerable regimen. J. clin. Oncol. 12 (1994), 553-559.
21. Hochster, H., J. Speyer, S. Wandler, C. Runowicz, R. Wallach, R. Oratz, A. Chachoua, J. Sorich, B. Taubes, E. Ludwig, C. Broom, R. Blum: Phase II study of topotecan (TPT) 21 day infusion in platinum-treated ovarian cancer. Proc. ASCO (1996), abstract 775.
22. Janss, A. J., Cnaan, A., A. Spilsky, C. Levow, Y. Yao, P. C. Philips: Synergistic cytotoxic effects of camptothecin and topotecan with alkylating agents are drug-specific and dose-dependent in human brain tumor cell lines. Proc. Amer. Ass. Cancer Res. 37 (1996), abstract 1996.
23. Kim, J. H., Kim, S. H., Kolozsvary, A., M. S. Khil: Potentiation of radiation response in human carcinoma cells in vitro in marine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I. Int. J. Radiat. Oncol. Biol. Phys. 22 (1992), 515-518.
24. Kudelka, A. P., D. Tresukosol, C. L. Edwards, R. S. Freedman, C. Levenback: Phase II-study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J. clin. Oncol. 14 (1996), 1552-1557.
25. Kuhn, J., S. Burris, J. Wall, T. Brown, J. Cagnole, K. Havlin, G. Weiss, J. Koeller, G. Rodriguez: Pharmakokinetics of the topoisomerase I inhibitor SK&F 104864. Proc. ASCO 9(1990), 70.
26. Liu, L. F.: DNA-topoisomerase poisons as antitumor drugs. Ann. Rev. Biochem. 58 (1989), 351-375.
27. MacDonald, D, G. Cairncross, D. Stewart, P. Forsyth, C. Sawka, N. Wainman, E. Eisenhauer: Phase II study of topotecan with recurrent malignant glioma. Ann. Oncol. 7 (1996), 205-207.
28. Malmström, H., B. Sorbe, E. Simonsen: The effect of topotecan in platinum refractory ovarian cancer. Proc. ASCO 15 (1996), abstract 829.
29. Marchesini, R., A. Colombo, C. Caserini, P. Perego, R. Supino, G. Capranico, M. Tronconi, F. Zunino: Interaction of ionizing radiation with topotecan in two human tumor cell lines. Int. J. Cancer 66 (1996), 342-346.
30. Mattern, R. M., G. A. Hofmann, F. L. McCabe, R. K. Johnson: Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864). Cancer Res. 51 (1991), 5813-5816.
31. Dwyer, P. J., C. Khater, C. Broom: Topotecan (Hycamtin): Current status of clinical trials. Proc. EORTC Drug Dev. Meeting, Corfu, June 1995.
32. Pawel, J. v., Wagner, H., Staab, H. J., J. Armbrecht: Therapeutische Wirksamkeit von Topotecan auf Hirnmetastasen bei Patienten mit kleinzelligem Bronchialkarzinom (SCLC) (Abstract). Essener Pulmologie-Kongreß, März 1996.
33. Schellens, J. H. M., J. R. Eckardt, D. D. von Hoff, G. J. Creemers, W. J. Loos, I. Hudson, C. Broom, B. E. Davies, J. Verweij: Pharmacokinetics, clinical pharmacodynamics and safety of chronic oral topotecan, in a phase I study. Europ. Cancer Conf. (ECCO) 8 (1995), abstract.
34. Sinha, B. K.: Topoisomerase-I-inhibitors: a review of their therapeutic potential in cancer. Drugs 49 (1995), 13-19.
35. Staab, H.-J.: Topoisomerase-I-Hemmung, ein neues Wirkprinzip in der Onkologie: Pharmakologie, Pharmakokineuk and Toxikologie des Topotecan. In: Staab, H-J., P. Drings: Neue therapeutische Prinzipien in der Krebsbehandlung. Thieme, Sruttgart 1996, S. 54-73.
36. Steren, A., B. U. Sevin, J. Perras, R. Ramos, H. Nguyen, R. Angioli M. Rodriguez, O. Koechli, H. Averette: Topotecan: a novel radiation sensitizer. Gynec. Oncol. 52 (1994), 112.
37. Sung, C., S. M. Blaney, D. E. Cole, F. M. Baus, R. L. Dedrick: A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. Cancer Res. 54 (1994), 5118-122.
38. Tronconi, M., R. Supino, R. Marchesini, P. Perego, A. Colombo, F. Zunino: Interaction of topotecan with ionizing radiation in two human tumor cell lines. Proc. Amer. Ass. Cancer Res. 36 (1995), abstract 3642.
39. Weiss, R. B.: A phase I study of topotecan in combination with doxorubicin. Ann. Oncol. 5 (1994), abstract 474.